JW THERAP-B (02126) proposes to issue a total of approximately 61.1855 million subscription shares at a discount of approximately 2.97% to raise HK$160 million

JW THERAP-B (02126) announces that on November 15, 2026, the Company entered into subscription agreements with China Hongqiao Holdings Limited or its designated entities and Novo Vista Limited Partnership to issue a total of approximately 61.1855 million subscription shares at HK$2.615 per subscription share, representing a discount of approximately 2.97% to the closing price of HK$2.695 per share as quoted on the Stock Exchange on the last trading day, for an aggregate subscription amount of HK$160 million. The Company intends to use the total net proceeds from the subscription for the following purposes: approximately 40% for advancing the research and development of the Group's in vivo CAR-T product pipeline (including JWCAR306 and other candidate products), covering investigator-initiated trials (IIT), manufacturing process development and optimization, IND-enabling studies and other related R&D activities; approximately 30% for supporting the research and development of the Group's autologous CAR-T product pipeline (including JWCAR201 and JWCAR239 (a dual-target, dual-armored CD19/CD20 CAR-T candidate product)), focusing on advancing ongoing and planned clinical studies, generating clinical data, IND-enabling studies and manufacturing process optimization; approximately 20% for supporting the continued development and upgrading of the Group's technology platforms and manufacturing capabilities, including the purchase, replacement and upgrading of manufacturing and laboratory equipment, as well as improvements to existing manufacturing facilities and related infrastructure; and approximately 10% for supporting the Group's working capital requirements and general corporate purposes.